Literature DB >> 1914757

Definition for idiopathic gastric acid hypersecretion. A statistical and functional evaluation.

M J Collen1, M J Sheridan.   

Abstract

Zollinger-Ellison syndrome and other gastric acid hypersecretory states in which a specific etiology is identified are defined as a basal acid output of greater than 15.0 meq/hr. To determine the level of basal acid output that defines idiopathic gastric hypersecretion, basal acid outputs were investigated in normal subjects and patients with duodenal ulcers, and functional and statistical definitions for idiopathic gastric acid hypersecretion were developed. Sixty-five normal subjects were evaluated to define idiopathic gastric acid hypersecretion on a statistical basis, and 22 patients with refractory duodenal ulcers were evaluated to define idiopathic gastric acid hypersecretion on a functional basis. Mean basal acid output for the 65 normal subjects was 3.0 +/- 2.7 meq/hr. Even though the mean basal acid output for the group of 28 normal male subjects was slightly higher than for the group of 37 normal female subjects, the groups were not significantly different. The 95% confidence interval around the mean basal acid output for all normal subjects was 2.4-3.7 meq/hr, with little difference between the male and female groups. The mean basal acid output plus two standard deviations and the mean basal acid output plus three standard deviations for the 65 normal subjects were 8.4 meq/hr and 11.1 meq/hr, respectively. Of 109 patients with active duodenal ulcers treated for eight weeks with standard doses of antisecretory medication, 22 showed no healing as documented by endoscopy.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1914757     DOI: 10.1007/bf01296801

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  27 in total

1.  BASAL AND HISTALOG-STIMULATED GASTRIC SECRETION IN CONTROL SUBJECTS AND IN PATIENTS WITH PEPTIC ULCER OR GASTRIC CANCER.

Authors:  M I GROSSMAN; J B KIRSNER; I E GILLESPIE
Journal:  Gastroenterology       Date:  1963-07       Impact factor: 22.682

Review 2.  Initial therapy and relapse of duodenal ulcer: possible acid secretory mechanisms.

Authors:  S G Chiverton; R H Hunt
Journal:  Gastroenterology       Date:  1989-02       Impact factor: 22.682

3.  Augmented postprandial gastric acid secretion due to exposure to ranitidine in healthy subjects.

Authors:  K Frislid; E Aadland; A Berstad
Journal:  Scand J Gastroenterol       Date:  1986-01       Impact factor: 2.423

4.  Gastric analysis (basal acid output) in nonulcer dyspepsia.

Authors:  M J Collen
Journal:  Dig Dis Sci       Date:  1990-04       Impact factor: 3.199

5.  Basal gastric acid secretion in nonulcer dyspepsia with or without duodenitis.

Authors:  M J Collen; M J Loebenberg
Journal:  Dig Dis Sci       Date:  1989-02       Impact factor: 3.199

6.  Gastric secretion in duodenal ulcer, with particular reference to the diagnosis of Zollinger-Ellison syndrome.

Authors:  M D Kaye; J Rhodes; P Beck
Journal:  Gastroenterology       Date:  1970-04       Impact factor: 22.682

7.  Present status of histalog gastric analysis in man.

Authors:  R I Breuer; J B Kirsner
Journal:  Ann N Y Acad Sci       Date:  1967-01-26       Impact factor: 5.691

8.  Gastric secretion with ulcerogenic islet cell tumor. Importance of basal acid output.

Authors:  T Aoyagi; W H Summerskill
Journal:  Arch Intern Med       Date:  1966-05

9.  A reappraisal of clinical, roentgenographic, and endoscopic features of the Zollinger-Ellison syndrome.

Authors:  P T Regan; J R Malagelada
Journal:  Mayo Clin Proc       Date:  1978-01       Impact factor: 7.616

10.  Basal gastric acid secretion in children with atypical epigastric pain.

Authors:  M J Collen; C A Ciarleglio; V J Stanczak; W R Treem; J H Lewis
Journal:  Am J Gastroenterol       Date:  1988-09       Impact factor: 10.864

View more
  10 in total

1.  Comparison of omeprazole and ranitidine in treatment of refractory gastroesophageal reflux disease in patients with gastric acid hypersecretion.

Authors:  M J Collen; R M Strong
Journal:  Dig Dis Sci       Date:  1992-06       Impact factor: 3.199

2.  Idiopathic gastric acid hypersecretion. Comparison with Zollinger-Ellison syndrome.

Authors:  M J Collen; R T Jensen
Journal:  Dig Dis Sci       Date:  1994-07       Impact factor: 3.199

3.  Correlation between basal acid output and daily ranitidine dose required for therapy in Barrett's esophagus.

Authors:  M J Collen; D A Johnson
Journal:  Dig Dis Sci       Date:  1992-04       Impact factor: 3.199

4.  Zollinger-Ellison phenotype in the absence of hypergastrinemia and islet-cell tumor.

Authors:  Anish A Desai; James E McGuigan; Peter Draganov
Journal:  Int J Gastrointest Cancer       Date:  2005

5.  Ranitidine therapy in patients with idiopathic gastric acid hypersecretion. A prospective study.

Authors:  M J Collen; J F Wirshup
Journal:  Dig Dis Sci       Date:  1995-08       Impact factor: 3.199

6.  Giant duodenal ulcer. Evaluation of basal acid output, nonsteroidal antiinflammatory drug use, and ulcer complications.

Authors:  M J Collen; M J Santoro; Y K Chen
Journal:  Dig Dis Sci       Date:  1994-05       Impact factor: 3.199

7.  Basal acid output and gastric acid hypersecretion in gastroesophageal reflux disease. Correlation with ranitidine therapy.

Authors:  M J Collen; D A Johnson; M J Sheridan
Journal:  Dig Dis Sci       Date:  1994-02       Impact factor: 3.199

8.  Gastric ulcers differ from duodenal ulcers. Evaluation of basal acid output.

Authors:  M J Collen; M J Sheridan
Journal:  Dig Dis Sci       Date:  1993-12       Impact factor: 3.199

9.  Three-year oral pantoprazole administration is effective for patients with Zollinger-Ellison syndrome and other hypersecretory conditions.

Authors:  D C Metz; G M Comer; E Soffer; C E Forsmark; B Cryer; W Chey; J R Pisegna
Journal:  Aliment Pharmacol Ther       Date:  2006-02-01       Impact factor: 8.171

Review 10.  pH, healing rate, and symptom relief in patients with GERD.

Authors:  J Q Huang; R H Hunt
Journal:  Yale J Biol Med       Date:  1999 Mar-Jun
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.